1. Home
  2. MG vs BWAY Comparison

MG vs BWAY Comparison

Compare MG & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mistras Group Inc

MG

Mistras Group Inc

BUY

Current Price

$20.77

Market Cap

531.0M

ML Signal

BUY

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$13.14

Market Cap

578.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MG
BWAY
Founded
1978
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Military/Government/Technical
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
531.0M
578.5M
IPO Year
2008
2011

Fundamental Metrics

Financial Performance
Metric
MG
BWAY
Price
$20.77
$13.14
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.25
AVG Volume (30 Days)
252.5K
69.1K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.30
N/A
Revenue
$700,970,000.00
N/A
Revenue This Year
$5.47
$309.69
Revenue Next Year
$3.59
$26.21
P/E Ratio
$66.13
$81.98
Revenue Growth
N/A
N/A
52 Week Low
$9.37
$11.77
52 Week High
$20.40
$26.63

Technical Indicators

Market Signals
Indicator
MG
BWAY
Relative Strength Index (RSI) 66.17 37.30
Support Level $13.75 $11.90
Resistance Level N/A $14.83
Average True Range (ATR) 0.62 0.45
MACD 0.02 -0.05
Stochastic Oscillator 82.09 24.24

Price Performance

Historical Comparison
MG
BWAY

About MG Mistras Group Inc

MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International, and Products and Systems, of which key revenue is derived from the North America segment. The North America segment provides asset protection solutions, including NDT, inspection, and mechanical and engineering services, along with software, digital, and data services.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: